Eli Lilly Issues Urgent Warning Over Impurities in Compounded Tirzepatide
Eli Lilly has issued a formal warning regarding "potentially dangerous" impurities discovered in compounded versions of its tirzepatide-based medications, Mounjaro and Zepbound. The company’s internal testing revealed significant safety risks in off-brand formulations, intensifying the ongoing conflict between big pharma and compounding pharmacies.